Showing 3271-3280 of 4063 results for "".
- Johnson & Johnson Vision Presents Data at #Academy23 on ACUVUE MAX 1-Day Contact Lenseshttps://modernod.com/news/johnson-johnson-vision-presents-data-at-academy23-on-acuvue-max-1-day-contact-lenses/2481885/Johnson & Johnson Vision will present data on the ACUVUE OASYS MAX 1-Day brand family of lenses and research on myopia progression, along with learning opportunities and support of Sight for Kids at the Academy 2023 New Orleans meeting, October 11–14. In celebration
- Alcon Showcases New TOTAL30 Multifocal Lenses and Other Innovations at #Academy23https://modernod.com/news/alcon-demonstrates-commitment-to-innovation-at-academy23-showcasing-total30-multifocal/2481884/Alcon will introduce TOTAL30 Multifocal, the first and only reusable Water Gradient multifocal contact lens, along with the latest advancements in eye care technology at the American Academy of Optometry Annual Meeting (#Academy23) in New Orleans, October 11-14, 2023. Alcon&rs
- OKYO Pharma Announces Filing of an IND Application for OK-101 to Treat Neuropathic Corneal Painhttps://modernod.com/news/okyo-pharma-announces-filing-of-an-ind-application-for-ok-101-to-treat-neuropathic-corneal-pain/2481882/OKYO Pharma announced that it filed an investigational new drug (IND) application with the FDA for the development of OK-101 to treat Neuropathic Corneal Pain (NCP). Study enrollment is planned to commence during Q1 2024 following IND allowance by the FDA. There is no FDA-appr
- Genentech’s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to 4 Months for People with RVO in Phase 3 Trialshttps://modernod.com/news/genentechs-vabysmo-maintained-vision-improvements-with-extended-treatment-intervals-up-to-4-months-for-people-with-rvo-in-phase-3-trials/2481878/Genentech announced positive topline long-term results from the global phase 3 BALATON and COMINO studies evaluating extended treatment intervals with Vabysmo (faricimab-svoa) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO). From weeks 24 to 7
- Phase 3 Stage 1 DIAMOND Trial Results of Oculis' OCS-01 in DME Presented at Euretinahttps://modernod.com/news/phase-3-stage-1-diamond-trial-results-of-oculis-ocs-01-in-dme-presented-euretina/2481877/Oculis announced that Professor Ramin Tadayoni, MD, PhD, presented the positive results from stage 1 of the phase 3 DIAMOND trial of OCS-01 in patients with DME at the 23rd EURETINA congress in Amsterdam. The data showed that the trial met primary and secondary endpoints
- Bausch + Lomb Launches New Range of Pure‐Line Gases at Euretinahttps://modernod.com/news/bausch-lomb-launches-new-range-of-pureline-gases-at-euretina-1/2481869/Bausch + Lomb announced the European launch of the new range of Pure‐line gases during the European Society of Retina Specialists (Euretina) annual meeting, taking place in Amsterdam, The Netherlands, Oct. 5‐ 8, 2023. Designed for ease of use, the Pure‐line gases are available as both p
- Oculis to Present a Late-Breaking Abstract at Euretina on Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edemahttps://modernod.com/news/oculis-to-present-a-late-breaking-abstract-at-euretina-on-phase-3-stage-1-diamond-trial-results-for-diabetic-macular-edema/2481867/Oculis announced that the positive readout from Stage 1 of its phase 3 DIAMOND trial of OCS-01 in patients with diabetic macular edema (DME) will be presented as a late-breaking abstract at the 23rd Euretina Congress, taking place October 5-8, 2023 in Amsterdam, the Netherlands.
- Nanoscope Therapeutics Announces Presentations at Upcoming Conferenceshttps://modernod.com/news/nanoscope-therapeutics-announces-presentations-at-upcoming-conferences/2481862/Nanoscope Therapeutics, which is developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), is scheduled to participate in the 2023 Ophthalmology Futures Retina Forum and Euretina Innovation Spotlight at the 23rd Euretina Congress, each taking place
- Thea Pharma Announces the US Launch of Glaucoma Drug Iyuzehhttps://modernod.com/news/thea-pharma-announces-the-us-launch-of-glaucoma-drug-iyuzeh/2481850/Thea Pharma announced the launch and availability of Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh, which received FDA approval in December 2022, is the first and only preservative-free latanoprost for patients with primary open-angle glaucoma (
- BostonSight Receives MMAP Grant to Expand and Automate Scleral Lens Manufacturinghttps://modernod.com/news/bostonsight-receives-mmap-grant-to-expand-and-automate-scleral-lens-manufacturing/2481848/BostonSight, a nonprofit healthcare organization that advances the treatment of diseased and damaged corneas and dry eye, announced it has received a $200,000 manufacturing grant from the Massachusetts Manufacturing Accelerate Program (MMAP) to advance its scleral lens manufacturing capabili